FDA Mandates New Study and Warnings on Labels for SGLT2 Inhibitors

Washington, DC: A review by the US Food and Drug Administration (FDA) of specific class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors, has resulted in the agency adding warnings to the labels concerning the risks for serious urinary tract infections (UTIs) too much acid in the blood. Both these conditions can result in hospitalization

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s